Because "every product is related to the life of a patient, so the quality of every product is related to the life of the enterprise." Therefore, the quality management concept of "10000-1=0" has been y rooted in the hearts of people in Weigao. They y understand the connotation of the service concept of "Quality First, Customer Satisfaction". They regard quality as the most crucial guarantee for brand creation, and put forward the idea of "seeking quality from management, seeking brand from quality, seeking market from brand, and seeking benefits from market". In order to put quality management into practice, Weigao Group Company, branch (sub) companies, workshop supervision at all levels, workshop, team, process road defense, strengthen the responsibility, strict management, everyone has the right to veto; raw materials into the company, into the warehouse, production, factory, ring have the right to veto, and resolutely put an end to the unqualified raw materials into the factory as well as the unqualified products out of the factory. Once, a workshop quality inspector found in the sampling inspection, a blood bag loading slightly insufficient, and this batch of products will be delivered to customers the next day. However, they immediately organized personnel to work overnight to reweigh the 400 boxes of blood bags that had been loaded. As a result, it was found that only this one blood bag had weighing problems. The head of the company said, in quality management, one ten-thousandth of the possible mistakes can not be spared.
In order to improve product quality, Weigao Group also introduced advanced production equipment from Japan, South Korea, the United States, the Netherlands, Singapore and other countries, such as medical needle production line, orthopedic material production line, medical catheter production line, prefilled syringe production line and so on, and these highly automated equipments provide a reliable guarantee for the standardization of production and the standardization of quality control. In addition, Weigao Group has built a testing organization that has reached the international advanced level. The testing center has imported advanced testing instruments such as liquid chromatograph and gas chromatograph from Japan and Switzerland. This is the only testing institution in China's medical device industry that has been accredited by the National Laboratory Accreditation Committee, and the test reports issued by them have international validity and can be recognized by the Asia-Pacific region and even other countries in the world.
It is these strict quality management and assurance systems that provide a strong guarantee for the production of high-quality products. 1998, Weigao Group took the lead in the industry to pass the ISO9000 quality management system certification, and in 1999, it took the lead in the industry to pass the European Union's CE standard certification, and the production of transfusion equipment passed the GMP certification. 2005 June, Weigao Group's "Jierui" is the only medical device in China that has passed the National Laboratory Accreditation Committee's accreditation. In June 2005, Weigao Group's "Jierui" trademark was recognized by the State Administration for Industry and Commerce as the first Chinese Well-known Trademark in China's medical equipment industry; in September 2006, "Jierui" brand single-use infusion medical equipment series products were awarded the title of China Famous Brand, and the "Jierui" brand was awarded the title of "China Famous Brand". In September 2006, "Jereh" brand disposable infusion medical equipment series won the title of Chinese famous brand, and "Jereh" brand products were designated as national inspection-free products. Nowadays, "Jereh" has not only won wide praise and established a good image among users in 30 provinces, municipalities and autonomous regions in China, but also sells well in 30 countries and regions such as the United States, Brazil, Germany, Russia, South Africa and India. Cardiac drug stent is a high-tech product for the treatment of coronary heart disease, which transmits the drug stent to the diseased area to support the narrowed blood vessels through interventional surgery. For a long time, China's cardiac drug stent market has been the world of large European and American enterprises, who hold the most critical technology, and the price of the product is extremely expensive, which is difficult for ordinary patients to afford. After painstaking research, Weigao Group has developed a cardiac drug-coated stent with independent intellectual property rights, which creatively changes the medication from spraying layer to coating, and all technical indexes have reached the international advanced level, and the price has been reduced by about 30% compared with foreign products. The introduction of this product has broken the long-term monopoly of foreign strong enterprises on China's cardiac drug-coated stent market, and enabled China to get rid of the situation of being controlled by others in the use of this product, and greatly reduced the burden of patients.
There are many other products with independent intellectual property rights like cardiac drug-coated stents in Weigao. Prefilled syringe is a high-level medicine package, which puts liquid drugs directly into the syringe for preservation, which is simple and convenient to use, while the syringe itself has good sealing so that the drugs can be stored for a long time. The product has been widely used in Europe and the United States and other developed countries, but in China is just beginning, and all monopolized by foreign enterprises, the price remains high. in November 2005, Weigao Group developed with independent intellectual property rights of the prefilled syringes, the price is cheaper than foreign products by more than 10%.
Relying on independent innovation to adjust the product structure, seize the technological high ground and adapt to the highly competitive market is an important strategic policy of Weigao Group. In order to keep abreast of the progress of the current technology and track the latest development of domestic and foreign technology, the company has strengthened its ties with relevant research institutes, and has cooperated with Changchun Institute of Applied Chemistry of the Chinese Academy of Sciences, Dalian Institute of Physics and Chemistry, Beijing 301 Hospital, Southwest Hospital of the Third Military Medical University and other scientific research institutes, and has established 9 R&D centers off-site, with the first-class innovation and R&D platforms in the industry. Weigao also pays great attention to the construction of talent team and investment in product research and development, the company annually spends more than 5% of its sales revenue on new product research and development; the company has hired 6 academicians of the Chinese Academy of Sciences and the Chinese Academy of Engineering as consultants; it has set up a postdoctoral research workstation, with 9 PhDs and postdocs; it has established a relationship of supply and demand for talents with Qingdao University of Science and Technology, Sichuan University and other domestic higher education institutions, attracting talents to join it; it has established a training center in Shanghai Vocational University to provide training for its students and students. We have established supply and demand relationship with Qingdao University of Science and Technology and Sichuan University to attract talents to join us, and trained talents for industrialization in Shanghai Vocational University to form a one-stop talent introduction and training pattern of technology research and development, product trial and industrialization implementation.
In recent years, Weigao Group has also continued to improve its technological innovation system, established a four-level technological innovation platform at the national, provincial, municipal and enterprise levels, and strengthened the cooperation among industries, universities and research institutes. Weigao Group further integrates the innovation institutions, strengthens the management of new product development, and formulates the "R&D Management System", which standardizes the whole process from the product project to the acceptance of the R&D products. The company holds a monthly R&D project work report meeting, rationally allocates R&D resources, and strengthens plan control to rationally use R&D funds. Disposable Hollow Fiber Plasma Separator, Type A Blood Collection Device, Spring Self-Destructing Safety Syringe, Medical Light Avoiding Plastic ...... Nowadays, Weigao Group has more than 100 patented products, of which 21 have reached the domestic leading level. Strong independent innovation ability and continuously rising level of independent research and development have given Weigao the right to speak in the international market and the initiative to develop. In 2005, Weigao Group actively contacted a medical equipment enterprise in the U.S. Through negotiation, the two sides reached a cooperative production and sales agreement on the basis of mutual benefit, and the products were labeled and sold by the enterprise in the U.S. as an agent. This is just one of the initiatives of Weigao Group to promote the Chinese national brand in the international market. Facing the market environment of global economic integration, Weigao people understand that if the enterprise is not integrated into the international market, the brand promotion of the enterprise will be limited and the development of the enterprise will be hindered. Without occupying a place in the international market, it is also difficult to establish a national brand. Therefore, in the late 90s of last century, Weigao people began to launch international marketing, and actively pushed into the international market. Germany, Britain, Russia, Belgium, the United States, Malaysia, Brazil and other more than 20 countries and regions, some merchants, users, keenly discovered the "Jieri" brand growth advantages, have ordered "Jieri" products.
After 2000, Weigao Group further increased the protection of the brand at home and abroad, so that trademark protection is in line with international standards. Domestically, Weigao Group started to use the trademark of "Jierui" at the beginning of its establishment, and the types of its trademark protection have reached 31; internationally, it has registered its trademarks in 20 countries such as Cuba, Germany, Egypt, France, Russia, Vietnam, Britain, Turkey, etc., so that the brand of "Jierui" is sold in foreign countries. The sales of "Jieri" brand in foreign countries have entered a stage of rapid growth.
In 2001, Weigao Group formulated a new export strategy for its products, expanding the original main target of Southeast Asia market to the global market, focusing on the European and African markets, and established a professional export sales team. They stabilized the main customers and optimized the market resources by strengthening the sales in the Middle East, Asia and other markets, and driving the sales to Europe and the United States through the relationship channels of the original customers. Through the business relationship with a customer in Iran, the Group has secured an order of nearly 30 million products from a company in Bulgaria; seizing the opportunity of economic development in Russia and other CIS countries, the Group has improved the sales of enterprises in the Russian market, radiated the neighboring countries, and widely expanded the market in Northern Europe. At the same time, they also carry out various forms of cooperation with foreign enterprises to expand overseas trade by utilizing labeling production or agency sales. Strengthen the internationalization standard of the enterprise. In addition to passing the CE certification of the European Union, they also work on the FDA certification of the U.S. Syringes, pumps, feeders and other products have passed the 510K license issued by the FDA, thus clearing the way for the smooth export of products to the United States.
On February 27, 2004, Weigao Group Medical Polymer Products Co., Ltd. was successfully listed on the Hong Kong Growth Enterprise Market, which not only finances the development and production of high-tech products, but also connects with the international community in many ways through the listing and enhances the international popularity of the company and its products. Nowadays, the national brand of Weigao Group is moving towards the international first-class level.